Prenetics Global Limited (NASDAQ:PRE) Short Interest Down 17.6% in February

Prenetics Global Limited (NASDAQ:PRE) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 32,800 shares, a decrease of 17.6% from the February 13th total of 39,800 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is presently 2.4 days. Currently, 0.4% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 target price on shares of Prenetics Global in a report on Thursday, January 16th.

Prenetics Global Price Performance

Shares of PRE traded down $0.19 during midday trading on Wednesday, hitting $4.16. The stock had a trading volume of 5,807 shares, compared to its average volume of 39,312. The stock’s 50 day moving average is $5.26 and its 200 day moving average is $4.96. The firm has a market cap of $50.82 million, a PE ratio of -1.04 and a beta of -0.31. Prenetics Global has a 1 year low of $2.85 and a 1 year high of $7.84.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new position in Prenetics Global Limited (NASDAQ:PRE) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent filing with the Securities and Exchange Commission (SEC). 25.01% of the stock is owned by hedge funds and other institutional investors.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.